Why the study?
Conflicting evidence exists regarding SERCA2a expression and activity in HFpEF, and its direct pathophysiological role remains undetermined.
What is the role of SERCA2a dysfunction in the pathophysiology of heart failure with preserved ejection fraction?
What is the role of SERCA2a dysfunction in the pathophysiology of heart failure with preserved ejection fraction?
The direct role of SERCA2a dysfunction in HFpEF remains undetermined, highlighting the need for further pre-clinical and clinical studies.
Answers are grounded in this paper and cite their sources.
No clinical role for SERCA2a modulation in HFpEF yet; leaves open its direct contribution for targeted trials.
-ATPase (SERCA2a), may play a significant role in its pathophysiology. A better understanding of the complex mechanisms interplaying to contribute to SERCA2a dysfunction will help develop treatments targeting it and thus address the growing clinical challenge HFpEF poses. This review examines the conflicting evidence present for changes in SERCA2a expression and activity in HFpEF, explores potential underlying mechanisms, and finally evaluates the drug and gene therapy trials targeting SERCA2a in heart failure. Recent positive results from trials involving widely used anti-diabetic agents such as sodium-glucose co-transporter protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) agonists offer advancement in HFpEF management. The potential interplay between these agents and SERCA2a regulation presents a novel angle that could open new avenues for modulating diastolic function; however, the mechanistic research in this emerging field is limited. Overall, the direct role of SERCA2a dysfunction in HFpEF remains undetermined, highlighting the need for well-designed pre-clinical studies and robust clinical trials.
No takes yet. Share an insight, caveat, or question.
Shooshtarian et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: